Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer

Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer

(2014) Nikhil Wagle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

(2014) Filip Janku et al.   Cell Reports

A Phase I Study of Temsirolimus and Thoracic Radiation in Non–Small-Cell Lung Cancer

(2013) Saiama N. Waqar et al.   Clinical Lung Cancer

A Phase 1 Study of Everolimus + Weekly Cisplatin + Intensity Modulated Radiation Therapy in Head-and-Neck Cancer

(2013) Matthew G. Fury et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

(2013) Prakash Chinnaiyan et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials

(2012) Roberto Iacovelli et al.   ACTA ONCOLOGICA

Radiation therapy and immunotherapy: Implications for a combined cancer treatment

(2012) Antonin Levy et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies

(2012) T. Eisen et al.   JNCI-Journal of the National Cancer Institute

Molecular pathology of lung cancer: key to personalized medicine

(2012) Liang Cheng et al.   MODERN PATHOLOGY

Genome Sequencing Identifies a Basis for Everolimus Sensitivity

(2012) G. Iyer et al.   SCIENCE

Long-Term Clinical Outcome of Intensity-Modulated Radiotherapy for Inoperable Non-Small Cell Lung Cancer: The MD Anderson Experience

(2011) Zhi-Qin Jiang et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Respiratory Gating Techniques for Optimization of Lung Cancer Radiotherapy

(2011) Philippe Giraud et al.   Journal of Thoracic Oncology

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER

North Central Cancer Treatment Group Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme

(2010) Jann N. Sarkaria et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

(2010) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL INVESTIGATION

Malignant Triton Tumor of the Brachial Plexus Invading the Left Thoracic Inlet: A Rare Differential Diagnosis of Pancoast Tumor

(2010) Jo Dartnell et al.   Journal of Thoracic Oncology

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

(2009) J.-C. Soria et al.   ANNALS OF ONCOLOGY

Class I PI3 Kinase Inhibition by the Pyridinylfuranopyrimidine Inhibitor PI-103 Enhances Tumor Radiosensitivity

(2008) R. Prevo et al.   CANCER RESEARCH

Antiangiogenic Therapy with Mammalian Target of Rapamycin Inhibitor RAD001 (Everolimus) Increases Radiosensitivity in Solid Cancer

(2008) P. C. Manegold et al.   CLINICAL CANCER RESEARCH

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

(2008) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY